LAMTOR5 and ovarian carcinoma: The strongly positive expression rate of HBXIP protein was 69.1% (56/81) in ovarian cancers with an advanced clinical stage (stage III–IV), which was significantly higher than in cases in the early clinical stage (stage I–II) (41.0%, 16/39).